Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Penumbra's accounts receivables for the quarter that ended in Jun. 2026 was $190 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Penumbra's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 44.55.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Penumbra's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was $14.70.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Penumbra's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Penumbra Accounts Receivable Related Terms
Penumbra Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Penumbra's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Penumbra (PEN) has a Accounts Receivable of $190 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Penumbra and its competitors.
Is Penumbra's Accounts Receivable too high?
Penumbra's current Accounts Receivable is $190 Mil. Overall, Penumbra has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Penumbra's Accounts Receivable compare to PODD and GMED?
Penumbra's Accounts Receivable of $190 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Devices & Instruments company?
A good Accounts Receivable depends on the Medical Devices & Instruments industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Penumbra and its competitors. Penumbra's current Accounts Receivable is $190 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Based on GuruFocus' analysis, Penumbra (PEN) is currently considered Fairly Valued. The stock's GF Value™ is $332.66, compared to a current price of $326.58 — trading 1.8% below its estimated fair value. The current Accounts Receivable is $190 Mil. Penumbra's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Penumbra (PEN), the current Accounts Receivable is $190 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Penumbra (PEN) Overvalued in 2026?
Based on GuruFocus' analysis, Penumbra stock appears to be undervalued.
The current stock price of $326.58 is trading 1.8% below its estimated GF Value™ of $332.66.
GuruFocus considers Penumbra to be Fairly Valued.
Key valuation signals for PEN:
Accounts Receivable: $190 Mil
GF Value™: $332.66 vs. price of $326.58 (1.8% below fair value)
No single metric tells the full story. See the PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
91GF Score
Get the complete analysis for PEN
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PEN has been successfully added to your 
